SKIP TO CONTENT
About Abbott
Contact
International | eng
Country Language

CARDIOVASCULAR

International | eng
Country Language

Supera™ Stent

Results Matter. Platform Matters.

Supera Stent
Clinical Evidence

Unmatched 1-Year Patency & 3-Year Freedom From TLR

The Supera™ Stent has been studied in over 2,000 patients worldwide in the SUPERB trial and 16 retrospective studies. Notably, in all of the 17 studies, the Supera™ Peripheral Stent showed durable results with zero fractures at 1 year.1,4-19
 

SUPERB Trial

At 1 year the Supera™ Stent demonstrated primary patency of 91% when nominally* deployed. At 3 years, freedom from targeted lesion revascularization (TLR) was 94% when nominally* deployed.1

91% patency at 1 year

PATENCY (K-M) AT 1 YEAR

When nominally deployed*

94% freedom from TLR at 3 years

FREEDOM FROM TLR AT 3 YEARS

When nominally deployed*


*Nominal deployment is defined as the stent length upon deployment being within +/- 10% of the labeled stent length. This data is from a non-powered post-hoc analysis. K-M=Kaplan Meier.

Consistent Patency Regardless of Lesion Length

With some peripheral stents, increasing lesion lengths can lead to decreasing patency rates.20 The Supera™ Stent stands apart for its consistently high patency rates in lesions spanning lengths from 5.3 cm up to 28.0 cm.†
 

consistently high patency rates

† Published data was included if lesion length and patency were both available.

Note: Results from different clinical trials are not directly comparable. Information provided for educational purposes only.

Excellent Results from Simple to Complex Lesions

Whether treating simple (TASC A&B) or complex (TASC C&D) lesions, the Supera™ Stent is associated with impressive, consistent patency performance data at 1 year.1-4

 

Simple
Simple lesionTrial/StudyMUNICH REGISTRY2SUPERB1
Lesion Length5.3cm7.8cm
TASC A&B Lesions100%94%
1-Yr
Patency		86.7%90.5%
SitesSingle CenterMulticenter (46 sites)
# Patients70264

 

Complex
Complex LesionTrial/StudyST. LOUIS4SUPERSUB3
Lesion Length24cm28cm
TASC C&D Lesions78%100%
CTOsUnknown100%
1-Yr
Patency		85.6%94.1%
SitesSingle CenterSingle Center
# Patients4834


TASC: Trans-Atlantic Inter-Society Consensus

REFERENCES

  1. Garcia L. et al., Catheterization and Cardiovascular Interventions 2017 Jun 1;89(7):1259-1267.
  2. Treitl, K.M., et al. European Radiology.2017; 10.1007.
  3. Palena L.M. et al. Catheterization and Cardiovascular Intervention.2016.
  4. Brescia AA. et al., J Vasc Surg. 2015 Jun;61(6):1472-8
  5. George JC. et al., J Vasc Interv Radiol. 2014 Jun;25(6):954-61.
  6. Montero-Baker M. et al., J Vasc Surg. 2016 Oct;64(4):1002-8.
  7. Scheinert D. et al., J Endovasc Ther. 2011 Dec;18(6):745-52.
  8. Werner M. et al., EuroIntervention. 2014 Nov;10(7):861-8.
  9. San Norberto EM. et al., Ann Vasc Surg. 2017 May;41:186-195.
  10. Chan YC. et al., J Vasc Surg. 2015 Nov;62(5):1201-9.
  11. Dumantepe M. Vasc Endovascular Surg. 2017 Jul;51(5):240-246.
  12. Goltz JP. et al., J Endovasc Ther. 2012 Jun;19(3):450-6.
  13. León LR Jr. et al., J Vasc Surg. 2013 Apr;57(4):1014-22.
  14. Myint M. et al., J Endovasc Ther. 2016 Jun;23(3):433-41.
  15. Palena LM. et al., J Endovasc Ther. 2018 Oct;25(5):588-591.
  16. Scheinert D. et al., JACC Cardiovasc Interv. 2013 Jan;6(1):65-71.
  17. Steiner S. et al., J Endovasc Ther. 2016 Apr;23(2):347-55.
  18. Teymen B. et al., Vascular. 2018 Feb;26(1):54-61.
  19. Bhatt H. et al., Cardiovasc Revasc Med. 2018 Jul;19(5 Pt A):512-515.
  20. Shroë H. Superficial femoral artery PTA or stenting? 5-Year results. CIRSE 2011; Munich, Germany

MAT-2106532 v2.0

POLICIES & ADVISORIES
HEALTHCARE PROFESSIONALS
PATIENTS & CAREGIVERS
Abbott logo

Information contained herein for distribution outside the U.S. only.

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

© 2024 Abbott. All Rights Reserved.

MAT-2001111 v7.0

Disclaimer

You are about to enter an Abbott country- or region-specific website. 

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions

Do you wish to continue and enter this website? 

YES

MAT-2305078 v1.0